Evidence map›Paper›PMID 42831160›Full record

ArticleCureus2026

Pure Red Cell Aplasia Associated With Thymoma: A Case Report.

Amine Benslimane, Layla Mohib, Soumaya El Yakoubi, Youssef Mahdi, Chaimaa Aboumedian, Roda Hassan Eltigani, Ibrahim El Ghissassi, Basma El Khannoussi, Hassan Errihani

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amine BenslimaneDepartment of Medical Oncology, National Institute of Oncology, Rabat, MAR.
Layla MohibDepartment of Medical Oncology, National Institute of Oncology, Rabat, MAR.
Soumaya El YakoubiDepartment of Medical Oncology, National Institute of Oncology, Rabat, MAR.
Youssef MahdiDepartment of Pathology, National Institute of Oncology, Rabat, MAR.
Chaimaa AboumedianDepartment of Medical Oncology, National Institute of Oncology, Rabat, MAR.
Roda Hassan EltiganiDepartment of Medical Oncology, National Institute of Oncology, Rabat, MAR.
Ibrahim El GhissassiDepartment of Medical Oncology, National Institute of Oncology, Rabat, MAR.
Basma El KhannoussiDepartment of Pathology, National Institute of Oncology, Rabat, MAR.
Hassan ErrihaniDepartment of Medical Oncology, National Institute of Oncology, Rabat, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 55-year-old male, former smoker, presented with exertional dyspnea associated with an anterior mediastinal mass. Biopsy findings were consistent with a type B2 thymoma. The tumor was deemed unresectable, and curative concurrent chemoradiotherapy was not feasible after three cycles of cyclophosphamide, adriamycin (doxorubicin), and platinum (cisplatin) (CAP) chemotherapy. Treatment was therefore continued to six cycles. Following radiological progression, second-line chemotherapy with paclitaxel and carboplatin was initiated. After two cycles, the patient developed superior vena cava syndrome. Palliative mediastinal radiotherapy was subsequently delivered. The patient experienced five episodes of severe hyporegenerative anemia, in the absence of bleeding or hemolysis, requiring repeated blood transfusions. Both the bone marrow aspirate and the bone marrow biopsy revealed pure red cell aplasia (PRCA). Testing for parvovirus B19 infection was negative. Immunosuppressive therapy with prednisone, combined with third-line etoposide-based chemotherapy, was initiated. However, the patient discontinued treatment after two cycles and remained transfusion-dependent during follow-up. This case highlights the diagnostic and therapeutic challenges posed by thymoma-associated PRCA in patients with advanced unresectable disease.

Indexed as

autoimmune diseasechemotherapyimmunosuppressive therapypure red cell aplasiathymoma

Identifiers

PMID42831160
PMCPMC13634494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.